Stockreport

Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer...

Zai Lab Limited - American Depositary Shares  (ZLAB) 
US:NASDAQ Investor Relations: zailaboratory.com/about/investors.php
PDF - Robust responses observed in heavily pre-treated patients with a 68% ORR for 1.6 mg/kg in second-line setting-Compelling activity in patients with baseline brain metas [Read more]